Skip to main content

Table 2 Reasons for operation following treatment with Imatinib

From: Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial

Patient N Age at surgery Tumor location Best % tumor shrikage Time to surgery reason for operation
4 43 Rectum -47 12,1 Significant response after 12 months on imatinib, enabling tumor resection
6 66 Mesentery -63 6,7 Large tumor lesion, decision to operate following tumor shrinkage on imatinib
7 81 Rectum -47 8,1 After initial response, patient had early signs of progression (increased blood flow on DCE-ultrasound) and was therefore operated before actual RECIST progression
8 40 Rectum -46 7,3 Surgery enabled following tumor shrinkage
12 43 Small bowel -74 6,5 Surgery planned prior to treatment with imatinib (true neoadjuvant)
13 61 Small bowel -74 11,7 Surgery enabled following tumor shrinkage
14 71 Small bowel 20 3,4 Rapid progression on imatinib 400 mg/d, dose increased to 600 mg/d which was poorly tolerated, salvage surgery seemed feasible. Resection was R1
15 76 Stomach 5 4,4 No response on imatinib with poor tolerance. Following surgery this patient was restarted on a lower dose of IM.
16 50 Small bowel -19 7,3 Stable disease after 6 months on imatinib, surgery was deemed feasible by surgeon.